Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation

Xinqi Zhang; Mingxi Yang; Hua Shi; Jianxin Hu; Yuanlin Wang; Zhaolin Sun; Shuxiong Xu

doi:10.18632/oncotarget.15361

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation

Xinqi Zhang, Mingxi Yang, Hua Shi, Jianxin Hu, Yuanlin Wang, Zhaolin Sun and Shuxiong Xu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:19566-19576. https://doi.org/10.18632/oncotarget.15361

Metrics: PDF 2868 views | HTML 3216 views | ?

Abstract

Xinqi Zhang1, Mingxi Yang2, Hua Shi2, Jianxin Hu2, Yuanlin Wang2, Zhaolin Sun2, Shuxiong Xu2

1Emergency Department, General Hospital of Jinan Military Area, Jinan, Shandong, 250031, China

2Department of Urology, Guizhou Provincial People’s Hospital Affiliated to Guizhou Medical University, Guiyang, Guizhou, 550002, China

Correspondence to:

Shuxiong Xu, email: [email protected]

Keywords: renal cell carcinoma, E-cadherin, β-catenin, immunohistochemistry (IHC)

Received: September 26, 2016 Accepted: January 16, 2017 Published: February 15, 2017

ABSTRACT

Reduced expression of E-cadherin was observed in renal cell carcinoma (RCC). However, its potential clinical value and correlation with WNT/β-catenin signaling in RCC progression was still unclear. Immunohistochemical staining was performed in RCC tissue microarray to examine the expression status and prognosis value of E-cadherin and β-catenin. The potential role of E-cadherin in β-catenin translocation was analyzed with immunobloting assays. A significant negative correlation was observed between E-cadherin and β-catenin expression in RCC tissues. E-cadherin inhibits β-catenin translocation from membrane to cytoplasm in RCC tissues, which was an important step for WNT/β-catenin signaling. Reduced E-cadherin expression was associated with poor prognosis. More importantly, E-cadherin-/β-catenin⁺ was an independent detrimental factor for survival estimation of RCC patients. Reduced E-cadherin expression in RCC promoted cancer progression via WNT/β-catenin signaling pathway activation. E-cadherin/β-catenin provides a valuable prognosis marker for RCC, which may be an effective target for RCC therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15361

Publication Alerts

Post-Publication Promotion

Research Papers:

Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation

Abstract